Actinium has forged strong partnerships with companies globally who share our vision of bringing targeted radiotherapies to patients in need.
Below are our existing partnerships and collaborations including for our lead clinical program Iomab-B and our targeted radiotherapy technology platform that is being utilized in the development developing novel targeted radiotherapies for both solid tumors and blood cancers.
In April 2022, Actinium announced Immedica licensed the rights to commercialize Iomab-B (1-131 apamistamab) in the EU, Middle East and North Africa. Actinium received a $35 million upfront payment and is eligible to receive up to an additional $417 million in potential regulatory and sales milestones as well as royalties in the mid-twenty percent range of Iomab-B sales under the terms of the license agreement. Read more about this agreement in our press release.
In 2021, Actinium and Astellas announced a continuation of our collaborative research partnership focused on developing theranostics to both image and diagnose solid tumor cancers and treat them leveraging Actinium’s AWE technology platform to utilize the Ac-225 radioisotope warhead with select targeting agents owned by Astellas as part of its Rx+© initiative.
In February 2022, Actinium and AVEO entered into a research collaboration to develop a first in class HER3 (ErbB3) targeting radiotherapy using the Actinium-225 radioisotope warhead for solid tumors. AVEO's HER3 targeting antibodies are designed to inhibit both ligand-dependent and ligand-independent signaling. HER3 is a receptor that is typically expressed in many human cancers and has demonstrated preclinical activity in multiple tumor models.
In January 2022, we announced a Strategic Research Collaboration with EpicentRx, Inc. to combine targeted radiotherapy with EpicentRx’s CD47-SIRPα immunotherapy RRx-001, which has been studied in Phase 3 clinical trials in lung cancer.
To learn more about potential partnership opportunities, please contact us at email@example.com.